Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking
blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib
works in treating patients with pancreatic cancer that cannot be removed by surgery.